NEW YORK, March 23, 2022 /PRNewswire/ -- The Colorectal Cancer Therapeutics Market is expected to grow by USD 2.45 billion from 2021 to 2026, at a CAGR of 5.43% during the forecast period, according to Technavio. The report offers an up-to-date analysis and to know exact growth variance and the Y-O-Y growth rate Request a free sample report.
Key Market Drivers & Challenges:
The growing geriatric population is one of the primary reasons driving the global colorectal cancer treatments market. According to the Centers for Disease Control and Prevention, more than 90% of colorectal cancer diagnoses occur in adults aged 50 and over. According to figures from the World Bank and the National Institutes of Health (NIH), the worldwide elderly population is predicted to increase from 9.3 percent in 2020 to around 17 percent by 2050. As a result, the expanding geriatric population is likely to increase the number of colorectal cancer cases, propelling the market in question to rise during the forecast period.
However, the patent expiration of innovative medicines is one of the major hurdles to the global colorectal cancer treatments market's growth.
Download a free sample for highlights on market Drivers & Challenges affecting the
Colorectal Cancer Therapeutics Market.
The Colorectal Cancer Therapeutics Market is segmented as below:
- Type
- Targeted Therapy
- Immunotherapy
- Chemotherapy
- Geography
- North America
- Europe
- Asia
- Rest Of World (ROW)
Learn more about the additional trends impacting the future of the market and the
positive and negative consequences on the businesses., download a free sample:
https://www.technavio.com/talk-to-us?report=IRTNTR72411
Colorectal Cancer Therapeutics Market 2022-2026: Scope
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our colorectal cancer therapeutics market report covers the following areas:
- Colorectal Cancer Therapeutics Market size
- Colorectal Cancer Therapeutics Market trends
- Colorectal Cancer Therapeutics Market industry analysis
This study identifies the development of small molecule kinase inhibitors as one of the prime reasons driving the colorectal cancer therapeutics market growth during the next few years.
Vendor Insights
The growing competition in the market is compelling vendors to adopt various growth strategies such as promotional activities and spending on advertisements to improve the visibility of their services. Some vendors are also adopting inorganic growth strategies such as M&As to remain competitive in the market.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
- Accord Healthcare Ltd.
- Amgen Inc.
- Amneal Pharmaceuticals Inc.
- Bayer AG
- Biocon Ltd.
- Bristol-Myers Squibb Co.
- CK Hutchison Holdings Ltd.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Fresenius SE and Co. KGaA
- Hetero Drugs Ltd.
- Hikma Pharmaceuticals Plc
- Merck and Co. Inc.
- Ono Pharmaceutical Co. Ltd.
- Otsuka Holdings Co. Ltd.
- Pfizer Inc.
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
Find additional highlights on the growth strategies adopted by vendors and their product
offerings, Read Free Sample Report.
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will assist colorectal cancer therapeutics market growth during the next five years
- Estimation of the colorectal cancer therapeutics market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the colorectal cancer therapeutics market
- Analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of colorectal cancer therapeutics market vendors
We offer USD 1,000 worth of FREE customization at the time of purchase. Speak to our
Analyst now!
Related Reports:
Bispecific Antibodies for Cancer Market by Type and Geography - Forecast and Analysis 2022-2026
Spasticity Treatment Market by Type and Geography - Forecast and Analysis 2022-2026
Colorectal Cancer Therapeutics Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.43% |
Market growth 2022-2026 |
$ 2.45 billion |
Market structure |
Fragmented |
YoY growth (%) |
4.15 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 36% |
Key consumer countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Accord Healthcare Ltd., Amgen Inc., Amneal Pharmaceuticals Inc., Bayer AG, Biocon Ltd., Bristol-Myers Squibb Co., CK Hutchison Holdings Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Hetero Drugs Ltd., Hikma Pharmaceuticals Plc, Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.3 Market size 2021
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Type
- 5.1 Market segments
- Exhibit 24: Chart on Type - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
- 5.2 Comparison by Type
- Exhibit 26: Chart on Comparison by Type
- Exhibit 27: Data Table on Comparison by Type
- 5.3 Targeted therapy - Market size and forecast 2021-2026
- Exhibit 28: Chart on Targeted therapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Targeted therapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Targeted therapy - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Targeted therapy - Year-over-year growth 2021-2026 (%)
- 5.4 Immunotherapy - Market size and forecast 2021-2026
- Exhibit 32: Chart on Immunotherapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Immunotherapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Immunotherapy - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Immunotherapy - Year-over-year growth 2021-2026 (%)
- 5.5 Chemotherapy - Market size and forecast 2021-2026
- Exhibit 36: Chart on Chemotherapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 37: Data Table on Chemotherapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 38: Chart on Chemotherapy - Year-over-year growth 2021-2026 (%)
- Exhibit 39: Data Table on Chemotherapy - Year-over-year growth 2021-2026 (%)
- 5.6 Market opportunity by Type
- Exhibit 40: Market opportunity by Type ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 42: Chart on Market share by geography 2021-2026 (%)
- Exhibit 43: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 44: Chart on Geographic comparison
- Exhibit 45: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Germany - Market size and forecast 2021-2026
- Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.9 UK - Market size and forecast 2021-2026
- Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.10 Canada - Market size and forecast 2021-2026
- Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.11 China - Market size and forecast 2021-2026
- Exhibit 78: Chart on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 79: Data Table on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 80: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 81: Data Table on China - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 82: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.1 Market drivers
- 8.2 Market challenges
- 8.3 Impact of drivers and challenges
- Exhibit 83: Impact of drivers and challenges in 2021 and 2026
- 8.4 Market trends
9 Vendor Landscape
- 9.1 Overview
- 9.2 Vendor landscape
- Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 85: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 86: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 87: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 88: Matrix on vendor position and classification
- 10.3 Amgen Inc.
- Exhibit 89: Amgen Inc. - Overview
- Exhibit 90: Amgen Inc. - Business segments
- Exhibit 91: Amgen Inc. - Key offerings
- Exhibit 92: Amgen Inc. - Segment focus
- 10.4 Bayer AG
- Exhibit 93: Bayer AG - Overview
- Exhibit 94: Bayer AG - Business segments
- Exhibit 95: Bayer AG - Key news
- Exhibit 96: Bayer AG - Key offerings
- Exhibit 97: Bayer AG - Segment focus
- 10.5 Biocon Ltd.
- Exhibit 98: Biocon Ltd. - Overview
- Exhibit 99: Biocon Ltd. - Business segments
- Exhibit 100: Biocon Ltd. - Key offerings
- Exhibit 101: Biocon Ltd. - Segment focus
- 10.6 Bristol-Myers Squibb Co.
- Exhibit 102: Bristol-Myers Squibb Co. - Overview
- Exhibit 103: Bristol-Myers Squibb Co. - Product / Service
- Exhibit 104: Bristol-Myers Squibb Co. - Key offerings
- 10.7 Eli Lilly and Co.
- Exhibit 105: Eli Lilly and Co. - Overview
- Exhibit 106: Eli Lilly and Co. - Business segments
- Exhibit 107: Eli Lilly and Co. - Key offerings
- Exhibit 108: Eli Lilly and Co. - Segment focus
- 10.8 F. Hoffmann La Roche Ltd.
- Exhibit 109: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 110: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 111: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 112: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 113: F. Hoffmann La Roche Ltd. - Segment focus
- 10.9 Fresenius SE and Co. KGaA
- Exhibit 114: Fresenius SE and Co. KGaA - Overview
- Exhibit 115: Fresenius SE and Co. KGaA - Business segments
- Exhibit 116: Fresenius SE and Co. KGaA - Key offerings
- Exhibit 117: Fresenius SE and Co. KGaA - Segment focus
- 10.10 Merck and Co. Inc.
- Exhibit 118: Merck and Co. Inc. - Overview
- Exhibit 119: Merck and Co. Inc. - Business segments
- Exhibit 120: Merck and Co. Inc. - Key news
- Exhibit 121: Merck and Co. Inc. - Key offerings
- Exhibit 122: Merck and Co. Inc. - Segment focus
- 10.11 Sanofi SA
- Exhibit 123: Sanofi SA - Overview
- Exhibit 124: Sanofi SA - Business segments
- Exhibit 125: Sanofi SA - Key news
- Exhibit 126: Sanofi SA - Key offerings
- Exhibit 127: Sanofi SA - Segment focus
- 10.12 Viatris Inc.
- Exhibit 128: Viatris Inc. - Overview
- Exhibit 129: Viatris Inc. - Business segments
- Exhibit 130: Viatris Inc. - Key offerings
- Exhibit 131: Viatris Inc. - Segment focus
11 Appendix
- 11.1 Scope of the report
- 11.2 Inclusions and exclusions checklist
- Exhibit 132: Inclusions checklist
- Exhibit 133: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 134: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 135: Research methodology
- Exhibit 136: Validation techniques employed for market sizing
- Exhibit 137: Information sources
- 11.5 List of abbreviations
- Exhibit 138: List of abbreviations
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article